|1.||Sharma, Surinder Kumar: 2 articles (07/2013 - 04/2012)|
|2.||Gupta, Yogendra Kumar: 2 articles (07/2013 - 04/2012)|
|3.||Srivastava, Amita: 2 articles (07/2013 - 04/2012)|
|4.||Kumar, Gajendra: 2 articles (07/2013 - 04/2012)|
04/01/2012 - "In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia."
04/01/2012 - "Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. "
04/01/2012 - "Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study."
07/01/2013 - "Therefore, present study was designed to evaluate the effect of Arogyavardhini vati in Triton WR-1339-induced hyperlipidemia in rats. "
07/01/2013 - "for 7 days after inducing hyperlipidemia) and Arogyavardhini vati treated (50, 100, 200 mg/kg, p.o. "
07/01/2013 - "Anti-hyperlipidemic activity evaluation of Arogyavardhini vati against Triton WR-1339-induced hyperlipidemia in rats. "
10/01/1980 - "A double-blind clinical trial of Arogya-wardhani--an ayurvedic drug--in acute viral hepatitis."
01/01/1987 - "'Arogyavardhini'-an indigenous formulation was evaluated for its hepatoprotective activity in rats, using two models of carbon tetrachloride (CCl4) hepatic damage, one simulating vital hepatitis and the other simulating fatty change. "
05/01/1994 - "Effects of single doses of kumari asav, kumari kalp, arogyavardhini and tamra bhasma on lysosomal enzymes (acid phosphatase and beta-glucuronidase) of rat liver and kidney were studied during hepatitis induced by single 0.3 ml/kg body wt dose of CCl4. "
|3.||Carbon Tetrachloride (Tetrachloromethane)
|1.||Ayurvedic Medicine (Siddha Medicine)